| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Journal of Clinical Endocrinology & Metabolism, Vol 76, 91-96, Copyright © 1993 by Endocrine Society
ARTICLES |
SJ Holmes, EA Espiner, AM Richards, TG Yandle and C Frampton
Department of Endocrinology, Christchurch Hospital, New Zealand.
Brain Natriuretic Peptide (BNP) is a recently identified hormone which is secreted by the human heart and circulates in plasma. To determine the effects of pathophysiological levels of human BNP (hBNP), we have studied the integrated renal, hormonal, and hemodynamic response in six normal men receiving 2-h infusions of synthetic hBNP (2.0 pmol/kg.min) or placebo in random order. Steady state levels of hBNP (20-30 pmol/L), achieved at 90-120 min, were similar to levels observed in mild heart failure. Compared to placebo infusions, hBNP induced a greater than 2- fold increase in sodium excretion (P = 0.014) and suppressed plasma aldosterone (P < 0.004) to levels less than 50% of placebo values. These changes were associated with an increase in both plasma (P = 0.028) and urine excretion (P < 0.004) of cGMP. Effects on blood pressure were not statistically significant but increases in both heart rate (P < 0.0001) and plasma albumin (P = 0.007) after cessation of hBNP infusions indicate significant hemodynamic effects of hBNP. High MCR (5.8 +/- 0.7 L/min) yet slow disappearance rate (mean t1/2 22.6 min) indicate that hBNP has a large volume of distribution in humans. These studies show that hBNP, at plasma levels observed in patients with mild heart failure, has potentially important natriuretic, endocrine, and hemodynamic effects which are similar to those observed with comparable infusion rates of ANF.
This article has been cited by other articles:
![]() |
I. George, B. Morrow, K. Xu, G.-H. Yi, J. Holmes, E. X. Wu, Z. Li, A. A. Protter, M. C. Oz, and J. Wang Prolonged effects of B-type natriuretic peptide infusion on cardiac remodeling after sustained myocardial injury Am J Physiol Heart Circ Physiol, August 1, 2009; 297(2): H708 - H717. [Abstract] [Full Text] [PDF] |
||||
![]() |
S Dhar, G S Pressman, S Subramanian, S Kaul, S Gollamudi, E J Bloom, and V M Figueredo Natriuretic peptides and heart failure in the patient with chronic kidney disease: a review of current evidence Postgrad. Med. J., June 1, 2009; 85(1004): 299 - 302. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Simsic, W. T. Mahle, A. Cuadrado, P. M. Kirshbom, and K. O. Maher Hemodynamic Effects and Safety of Nesiritide in Neonates with Heart Failure J Intensive Care Med, November 1, 2008; 23(6): 389 - 395. [Abstract] [PDF] |
||||
![]() |
K. O. Maher, H. Reed, A. Cuadrado, J. Simsic, W. T. Mahle, M. DeGuzman, T. Leong, and S. Bandyopadhyay B-Type Natriuretic Peptide in the Emergency Diagnosis of Critical Heart Disease in Children Pediatrics, June 1, 2008; 121(6): e1484 - e1488. [Abstract] [Full Text] [PDF] |
||||
![]() |
R J Hillock, C M Frampton, T G Yandle, R W Troughton, J G Lainchbury, and A M Richards B-type natriuretic peptide infusions in acute myocardial infarction Heart, May 1, 2008; 94(5): 617 - 622. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. M. Witteles, D. Kao, D. Christopherson, K. Matsuda, R. H. Vagelos, D. Schreiber, and M. B. Fowler Impact of Nesiritide on Renal Function in Patients With Acute Decompensated Heart Failure and Pre-Existing Renal Dysfunction: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial J. Am. Coll. Cardiol., November 6, 2007; 50(19): 1835 - 1840. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. M. Mentzer Jr, M. C. Oz, R. N. Sladen, A. H. Graeve, R. F. Hebeler Jr, J. M. Luber Jr, N. G. Smedira, and on behalf of the NAPA Investigators Effects of Perioperative Nesiritide in Patients With Left Ventricular Dysfunction Undergoing Cardiac Surgery: The NAPA Trial J. Am. Coll. Cardiol., February 13, 2007; 49(6): 716 - 726. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Hazukova, M. Pleskot, and H. Stritecka Methodical approach to collecting and preserving plasma samples containing B-type natriuretic peptide Eur J Heart Fail, February 1, 2007; 9(2): 216 - 217. [Full Text] [PDF] |
||||
![]() |
M. H. Williams, C. E. Handler, R. Akram, C. J. Smith, C. Das, J. Smee, D. Nair, C. P. Denton, C. M. Black, and J. G. Coghlan Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension Eur. Heart J., June 2, 2006; 27(12): 1485 - 1494. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. L. Miller, K. A. Hartman, M. F. Burritt, D. D. Borgeson, J. C. Burnett Jr, and A. S. Jaffe Biomarker Responses during and after Treatment with Nesiritide Infusion in Patients with Decompensated Chronic Heart Failure Clin. Chem., March 1, 2005; 51(3): 569 - 577. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. M. Choi, K. H. Lee, B. L. Eun, K. H. Yoo, Y. S. Hong, C. S. Son, and J. W. Lee Utility of Rapid B-Type Natriuretic Peptide Assay for Diagnosis of Symptomatic Patent Ductus Arteriosus in Preterm Infants Pediatrics, March 1, 2005; 115(3): e255 - e261. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Wang, T. C. Dowling, D. Meadows, T. Ayala, J. Marshall, S. Minshall, N. Greenberg, E. Thattassery, M. L. Fisher, K. Rao, et al. Nesiritide Does Not Improve Renal Function in Patients With Chronic Heart Failure and Worsening Serum Creatinine Circulation, September 21, 2004; 110(12): 1620 - 1625. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. C. Kurian, I. J. Wagner, and M. Klapholz Nesiritide in Pulmonary Hypertension Chest, July 1, 2004; 126(1): 302 - 305. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. G. Wahl, S. Graf, H. Renz, and W. Fassbinder Elimination of the Cardiac Natriuretic Peptides B-Type Natriuretic Peptide (BNP) and N-Terminal proBNP by Hemodialysis Clin. Chem., June 1, 2004; 50(6): 1071 - 1074. [Full Text] [PDF] |
||||
![]() |
P.-Y. Marie, P. M. Mertes, N. Hassan-Sebbag, N. de Talence, K. Djaballah, W. Djaballah, J. Friberg, P. Olivier, G. Karcher, F. Zannad, et al. Exercise release of cardiac natriuretic peptides is markedly enhanced when patients with coronary artery disease are treated medically by beta-blockers J. Am. Coll. Cardiol., February 4, 2004; 43(3): 353 - 359. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Gegenhuber, T. Mueller, F. Firlinger, K. Lenz, W. Poelz, and M. Haltmayer Time Course of B-Type Natriuretic Peptide (BNP) and N-Terminal ProBNP Changes in Patients with Decompensated Heart Failure Clin. Chem., February 1, 2004; 50(2): 454 - 456. [Full Text] [PDF] |
||||
![]() |
U. Alehagen, G. Lindstedt, H. Eriksson, and U. Dahlstrom Utility of the Amino-Terminal Fragment of Pro-Brain Natriuretic Peptide in Plasma for the Evaluation of Cardiac Dysfunction in Elderly Patients in Primary Health Care Clin. Chem., August 1, 2003; 49(8): 1337 - 1346. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. van der Zander, A. J.H.M. Houben, A. A. Kroon, T. K.A. Wierema, M. J.M.J. Fuss-Lejeune, D. Koster, and P. W. de Leeuw Does Brain Natriuretic Peptide Have a Direct Renal Effect in Human Hypertensives? Hypertension, January 1, 2003; 41(1): 119 - 123. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. A. Sagnella Atrial natriuretic peptide mimetics and vasopeptidase inhibitors Cardiovasc Res, August 15, 2001; 51(3): 416 - 428. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Boomsma and A. H. van den Meiracker Plasma A- and B-type natriuretic peptides: physiology, methodology and clinical use Cardiovasc Res, August 15, 2001; 51(3): 442 - 449. [Full Text] [PDF] |
||||
![]() |
P. R Kalra, S. D Anker, and A. J.S Coats Water and sodium regulation in chronic heart failure: the role of natriuretic peptides and vasopressin Cardiovasc Res, August 15, 2001; 51(3): 495 - 509. [Full Text] [PDF] |
||||
![]() |
P.R Kalra, S.D Anker, A.D Struthers, and A.J.S Coats The role of C-type natriuretic peptide in cardiovascular medicine Eur. Heart J., June 2, 2001; 22(12): 997 - 1007. [PDF] |
||||
![]() |
G. A Sagnella Practical implications of current natriuretic peptide research Journal of Renin-Angiotensin-Aldosterone System, December 1, 2000; 1(4): 304 - 315. [PDF] |
||||
![]() |
W. S. Colucci, U. Elkayam, D. P. Horton, W. T. Abraham, R. C. Bourge, A. D. Johnson, L. E. Wagoner, M. M. Givertz, C.-s. Liang, M. Neibaur, et al. Intravenous Nesiritide, a Natriuretic Peptide, in the Treatment of Decompensated Congestive Heart Failure N. Engl. J. Med., July 27, 2000; 343(4): 246 - 253. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. van der Zander, A. J.H.M Houben, A. A Kroon, and P. W de Leeuw Effects of brain natriuretic peptide on forearm vasculature: comparison with atrial natriuretic peptide Cardiovasc Res, December 1, 1999; 44(3): 595 - 600. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.A.M Wijbenga, A.H.M.M Balk, F Boomsma, A.J Man in 't Veld, and C Hall Cardiac peptides differ in their response to exercise. Implications for patients with heart failure in clinical practice Eur. Heart J., October 1, 1999; 20(19): 1424 - 1428. [Abstract] [PDF] |
||||
![]() |
R. M. Mills, T. H. LeJemtel, D. P. Horton, C.-s. Liang, R. Lang, M. A. Silver, C. Lui, K. Chatterjee, and on Behalf of the Natrecor Study Group Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: A randomized, double-blind, placebo-controlled clinical trial J. Am. Coll. Cardiol., July 1, 1999; 34(1): 155 - 162. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. G. Lainchbury, M. G. Nicholls, E. A. Espiner, T. G. Yandle, L. K. Lewis, and A. M. Richards Bioactivity and Interactions of Adrenomedullin and Brain Natriuretic Peptide in Patients With Heart Failure Hypertension, July 1, 1999; 34(1): 70 - 75. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. L. Woods and M. J. M. Jones Atrial, B-type, and C-type natriuretic peptides cause mesenteric vasoconstriction in conscious dogs Am J Physiol Regulatory Integrative Comp Physiol, May 1, 1999; 276(5): R1443 - R1452. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. G. Lainchbury, A. M. Richards, M. G. Nicholls, E. A. Espiner, and T. G. Yandle Brain Natriuretic Peptide and Neutral Endopeptidase Inhibition in Left Ventricular Impairment J. Clin. Endocrinol. Metab., February 1, 1999; 84(2): 723 - 729. [Abstract] [Full Text] |
||||
![]() |
B. M. Y. Cheung and C. R. Kumana Natriuretic Peptides--Relevance in Cardiovascular Disease JAMA, December 16, 1998; 280(23): 1983 - 1984. [Full Text] [PDF] |
||||
![]() |
K. T. Jensen, J. Carstens, and E. B. Pedersen Effect of BNP on renal hemodynamics, tubular function and vasoactive hormones in humans Am J Physiol Renal Physiol, January 1, 1998; 274(1): F63 - F72. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. G. Lainchbury, A. M. Richards, M. G. Nicholls, P. J. Hunt, H. Ikram, E. A. Espiner, T. G. Yandle, and E. Begg The Effects of Pathophysiological Increments in Brain Natriuretic Peptide in Left Ventricular Systolic Dysfunction Hypertension, September 1, 1997; 30(3): 398 - 404. [Abstract] [Full Text] |
||||
![]() |
M. L. De Feo, G. La Villa, C. Lazzeri, C. Tosti-Guerra, A. Becorpi, C. Pupilli, and M. Mannelli Urinary Endothelin-1 Excretion Is Enhanced by Low-Dose Infusion of Brain Natriuretic Peptide in Normal Humans Hypertension, January 1, 1997; 29(1): 70 - 74. [Abstract] [Full Text] |
||||
![]() |
L. S. Marcus, D. Hart, M. Packer, M. Yushak, N. Medina, R. S. Danziger, D. F. Heitjan, and S. D. Katz Hemodynamic and Renal Excretory Effects of Human Brain Natriuretic Peptide Infusion in Patients With Congestive Heart Failure: A Double-Blind, Placebo-Controlled, Randomized Crossover Trial Circulation, December 15, 1996; 94(12): 3184 - 3189. [Abstract] [Full Text] |
||||
![]() |
P. B.M. Clarkson, N. M. Wheeldon, R. J. MacFadyen, S. D. Pringle, and T. M. MacDonald Effects of Brain Natriuretic Peptide on Exercise Hemodynamics and Neurohormones in Isolated Diastolic Heart Failure Circulation, June 1, 1996; 93(11): 2037 - 2042. [Abstract] [Full Text] |
||||
![]() |
G. B. Pidgeon, A. M. Richards, M. G. Nicholls, E. A. Espiner, T. G. Yandle, and C. Frampton Differing Metabolism and Bioactivity of Atrial and Brain Natriuretic Peptides in Essential Hypertension Hypertension, April 1, 1996; 27(4): 906 - 913. [Abstract] [Full Text] |
||||
![]() |
G. La Villa, L. Stefani, C. Lazzeri, C. Zurli, C. T. Guerra, G. Barletta, R. Bandinelli, G. Strazzulla, and F. Franchi Acute Effects of Physiological Increments of Brain Natriuretic Peptide in Humans Hypertension, October 1, 1995; 26(4): 628 - 633. [Abstract] [Full Text] |
||||
![]() |
G. La Villa, G. Bisi, C. Lazzeri, C. Fronzaroli, L. Stefani, G. Barletta, R. Del Bene, G. Messeri, G. Strazzulla, and F. Franchi Cardiovascular Effects of Brain Natriuretic Peptide in Essential Hypertension Hypertension, May 1, 1995; 25(5): 1053 - 1057. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |